

Number and percentage of persons linked to care<sup>e</sup> within 1, 3, 6, and 12 months<sup>f</sup> of their HIV infection diagnosis among persons who were ≥13 years of old at diagnosis, resided in Connecticut (based on residence of HIV disease diagnosis) and diagnosed with HIV infection between 01/01/2016 through 12/31/2016, by selected characteristics - based on HIV surveillance data reported through 12/21/2017.

Characteristics	Persons diagnosed with HIV infection	Persons linked to care within 1 months of diagnosis		Persons linked to care within 3 months of diagnosis		Persons linked to care within 6 months of diagnosis		Persons linked to care within 12 months of diagnosis <sup>g</sup>	
	No.	No.	%	No.	%	No.	%	No.	%
<b>Sex</b>									
Male	212	189	89.15	204	96.23	206	97.17	207	97.64
Female	55	46	83.64	50	90.91	50	90.91	53	96.36
<b>Age at diagnosis</b>									
13-24	49	40	81.63	46	93.88	47	95.92	47	95.92
25-34	84	75	89.29	81	96.43	81	96.43	81	96.43
35-44	42	35	83.33	39	92.86	39	92.86	41	97.62
45-54	50	45	90	48	96	48	96	49	98
55-64	29	29	100	29	100	29	100	29	100
≥65	13	11	84.62	11	84.62	12	92.31	13	100
<b>Race/ethnicity</b>									
Black/African American	109	91	83.49	101	92.66	102	93.58	104	95.41
Hispanic/Latino <sup>b</sup>	81	71	87.65	77	95.06	78	96.3	79	97.53
White	70	67	95.71	70	100	70	100	70	100
Other races	7	6	85.71	6	85.71	6	85.71	7	100
<b>Transmission category</b>									
Male-to-male sexual contact (MSM)	143	129	90.21	140	97.9	141	98.6	141	98.6
Injection drug use (IDU)	14	13	92.86	14	100	14	100	14	100
MSM and IDU	6	5	83.33	6	100	6	100	6	100
Heterosexual contact <sup>c</sup>	61	52	85.25	57	93.44	58	95.08	59	96.72
Other <sup>d</sup>	43	36	83.72	37	86.05	37	86.05	40	93.02
<b>MSM</b>									
Black/African American	41	36	87.8	40	97.56	40	97.56	40	97.56
Hispanic/Latino <sup>b</sup>	48	42	87.5	46	95.83	47	97.92	47	97.92
White	53	50	94.34	53	100	53	100	53	100
Other races	1	1	100	1	100	1	100	1	100
<b>Subtotal</b>	<b>143</b>	<b>129</b>	<b>90.21</b>	<b>140</b>	<b>97.9</b>	<b>141</b>	<b>98.6</b>	<b>141</b>	<b>98.6</b>
<b>Injection drug use (male)</b>									
Black/African American	3	3	100	3	100	3	100	3	100
Hispanic/Latino <sup>b</sup>	2	1	50	2	100	2	100	2	100
White	1	1	100	1	100	1	100	1	100
<b>Subtotal</b>	<b>6</b>	<b>5</b>	<b>83.33</b>	<b>6</b>	<b>100</b>	<b>6</b>	<b>100</b>	<b>6</b>	<b>100</b>
<b>Injection drug use (female)</b>									
Black/African American	3	3	100	3	100	3	100	3	100
Hispanic/Latino <sup>b</sup>	3	3	100	3	100	3	100	3	100
White	2	2	100	2	100	2	100	2	100
<b>Subtotal</b>	<b>8</b>	<b>8</b>	<b>100</b>	<b>8</b>	<b>100</b>	<b>8</b>	<b>100</b>	<b>8</b>	<b>100</b>
<b>Heterosexual contact (male)</b>									
Black/African American	19	16	84.21	17	89.47	18	94.74	18	94.74
Hispanic/Latino <sup>b</sup>	5	5	100	5	100	5	100	5	100
White	2	2	100	2	100	2	100	2	100
<b>Subtotal</b>	<b>26</b>	<b>23</b>	<b>88.46</b>	<b>24</b>	<b>92.31</b>	<b>25</b>	<b>96.15</b>	<b>25</b>	<b>96.15</b>
<b>Heterosexual contact (female)</b>									
Black/African American	26	21	80.77	24	92.31	24	92.31	25	96.15
Hispanic/Latino <sup>b</sup>	6	5	83.33	6	100	6	100	6	100
White	2	2	100	2	100	2	100	2	100
Other races	1	1	100	1	100	1	100	1	100
<b>Subtotal</b>	<b>35</b>	<b>29</b>	<b>82.86</b>	<b>33</b>	<b>94.29</b>	<b>33</b>	<b>94.29</b>	<b>34</b>	<b>97.14</b>
<b>Total</b>	<b>267</b>	<b>235</b>	<b>88.01</b>	<b>254</b>	<b>95.13</b>	<b>256</b>	<b>95.88</b>	<b>260</b>	<b>97.38</b>

<sup>a</sup>Hispanics/Latinos can be of any race.

<sup>b</sup>Heterosexual contact with person known to have, or to be at high risk for, HIV infection.

<sup>c</sup>Includes cases with risk factor not reported or not identified, and 1 cases with hemophilia, or blood transfusion, or perinatal exposure.

<sup>d</sup>Persons who have at least one CD4 or viral load or HIV-1 genotype test during a specific time period are considered as linked to care during that time.

<sup>e</sup>The months difference is calculated between diagnosis date of HIV infection and sample collection date, and only year and month are used in calculation.

<sup>f</sup>Numbers are underestimated for persons linked to care within 12 months of diagnosis because not every lab test result has at least 3 months after the test was done to allow that it was reported to local health departments. The end of the evaluation time period (12/31/2016) is only 11 Months before the PERSON-based dataset was exported from eHARS. CDC suggests that this date should be at least 15 months before the creation date of PERSON-based dataset.